We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Solid Biosciences Inc | NASDAQ:SLDB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.08 | 0.77% | 10.50 | 10.50 | 10.66 | 10.64 | 10.04 | 10.19 | 106,454 | 01:00:00 |
From Nov 2023 to May 2024
By Chris Wack
Solid Biosciences has been granted orphan drug designation from the U.S. Food and Drug Administration for SGT-003, the company's next-generation Duchenne muscular dystrophy gene therapy candidate.
The life-science company's SGT-003 received Fast Track Designation last month.
The company said it is currently in the process of securing approvals from the institutional review boards at the clinical trial sites for the planned Phase 1/2 clinical trial of SGT-003 and expects to begin patient screening shortly thereafter.
Patient dosing in the trial is expected to begin in mid-to-late first quarter of 2024.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 16, 2024 08:35 ET (13:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Solid Biosciences Chart |
1 Month Solid Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
